Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Acta Oncol 2019 Apr 17:1-10. Epub 2019 Apr 17.

a Institute of Neurology , Medical University of Vienna , Vienna , Austria.

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups.

Material And Methods: Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016). Prognostic factors and treatment-related data were integrated in a comprehensive survival analysis including conditional survival estimates.

Results: We find variable patterns of first-line treatment with increasing use of rituximab and high-dose methotrexate (HDMTX)-based poly-chemotherapy after 2007, paralleled by an increase in median overall survival restricted to patients aged below 70 years. In the entire cohort, 5-year overall survival was 24.4% while 5-year conditional survival increased with every year postdiagnosis.

Conclusion: In conclusion, we show that the use of poly-chemotherapy and immunotherapy has disseminated to community practice to a fair extent and survival has increased over time at least in younger patients. Annually increasing conditional survival rates provide clinicians with an adequate and encouraging prognostic measure.

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1599137DOI Listing
April 2019

Publication Analysis

Top Keywords

conditional survival
12
survival
9
primary cns
8
cns lymphoma
8
survival increased
8
younger patients
8
newly diagnosed
4
survival restricted
4
registry population-based
4
tumor registry
4
brain tumor
4
restricted patients
4
paralleled increase
4
population-based cohort
4
cohort 189
4
189 patients
4
patients aged
4
patients newly
4
median survival
4
increase median
4

References

(Supplied by CrossRef)

Similar Publications